3
Participants
Start Date
March 1, 2023
Primary Completion Date
December 1, 2024
Study Completion Date
December 1, 2024
OnabotulinumtoxinA 145 UNT [Botox]
"Botulinum A toxin injection: Will follow the FDA-approved guideline of the treatment of chronic migraine. The following modifications are planned: (a) Total units 145 instead of 155. (b) Number of injection sites 29 instead of 31. (c) the 6 injection sites in the trapezius muscle will be eliminated as they are irrelevant to our attempt to reduce seizure events. Instead, 4 injections will be made subcutaneously along the superior sagittal suture (see figures below), where no muscles exist and thus no muscle weakness is likely. This dose (145 Units) is well below the FDA-approved guideline on safety for adolescents and adults (no more than 10 Units/Kg or a total of 340 Units).~Botox injections will take place in the BIDMC Headache Clinic which is a part of the Arnold Pain center at 1 Brookline Place. Injections will be administered by Dr. Sait Ashina, the Director of the Headache Clinic."
Beth Israel Deaconess Medical Center, Boston
Collaborators (1)
AbbVie
INDUSTRY
Beth Israel Deaconess Medical Center
OTHER